1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Antibodies
3.2.1. Structure
3.2.2. Functions
3.2.3. Mechanism of Action
3.3. Antibody Therapeutics
3.3.1. Historical Evolution of Antibody Therapeutics
3.3.2. Key Approved Antibody Therapeutics
3.3.3. Advanced Antibody Therapeutics
3.3.3.1. Fc Engineered and Glycoengineered Antibodies
3.3.3.2. Antibody Fragments
3.3.3.3. Fusion Proteins
3.3.3.4. Intrabodies
3.3.3.5. Bispecific Antibodies
3.4. Bispecific Antibody Formats
3.4.1. Single-Chain-based Formats (Fc Independent Antibody Formats)
3.4.1.1. Tandem scFvs (single-chain variable fragments) and Triple bodies
3.4.1.2. Bispecific Single-Domain Antibody Fusion Proteins
3.4.1.3. Diabodies / Diabody Derivatives
3.4.1.4. Fusion Proteins
3.4.1.5. Fusion Proteins Devoid of Fc Regions
3.4.2. Immunoglobulin G Based Formats (Fc Dependent Antibody Formats)
3.4.2.1. Quadromas
3.4.2.2. Knobs-Into-Holes
3.4.2.3. Dual Variable Domain Ig
3.4.2.4. IgG-scFv
3.4.2.5. Two-in-one or Dual Action Fab (DAF) Antibodies
3.4.2.6. Half Molecule Exchange
3.4.2.7. ??- Bodies
3.5. Mechanism of Action of Bispecific Antibody Therapeutics
3.5.1. Retargeting Immune Effectors (NK Cells and T Cells) to Tumor Cells
3.5.2. Directly Targeting Malignant / Tumor Cells
3.5.3. Retargeting of Toxins
3.5.4. Targeting Tumor Angiogenesis
3.5.5. Other Mechanisms
3.6. Applications of Bispecific Antibodies
4. MARKET LANDSCAPE OF APPROVED AND CLINICAL THERAPIES
4.1. Chapter Overview
4.2. Approved and Clinical Bispecific Antibody Therapeutics: Overall Market Landscape
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Target Antigen
4.2.3. Analysis by Type of Therapy
4.2.4. Analysis by Route of Administration
4.2.5. Analysis by Method of Administration
4.2.6. Analysis by Target Indication
4.2.7. Analysis by Therapeutic Area
4.2.8. Analysis by Disease Segment
4.3. Approved and Clinical Bispecific Antibody Therapeutics: Overall Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
5. MARKET LANDSCAPE OF PRECLINICAL THERAPIES
5.1. Chapter Overview
5.2. Preclinical Bispecific Antibody Therapeutics: Overall Market Landscape
5.2.1. Analysis by Stage of Development
5.2.2. Analysis by Target Antigen
5.2.3. Analysis by Disease Segment
5.3. Preclinical Bispecific Antibody Therapeutics: Overall Developer Landscape
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size
5.3.3. Analysis by Location of Headquarters
6. KEY INSIGHTS
6.1. Chapter Overview
6.2. Approved and Clinical Stage Bispecific Antibody Therapeutics Landscape: Key Insights
6.2.1. Analysis by Phase of Development and Route of Administration
6.2.2. Analysis by Phase of Development and Disease Segment
6.2.3. Analysis by Phase of Development and Location of Developer’s Headquarters
6.3. Preclinical Stage Bispecific Antibody Therapeutics Landscape: Key Insights
6.3.1. Analysis by Stage of Development and Therapeutic Area
6.3.2. Analysis by Stage of Development and Location of Developer Headquarters
6.4. Bispecific Antibody Therapeutics Developers Landscape: Key Insights
6.4.1. Distribution by Stage of Development
6.4.2. Distribution by Stage of Development and Region of Developer Headquarters
7. TECHNOLOGY ASSESSMENT FRAMEWORK
7.1. Chapter Overview
7.2. Bispecific Antibody Therapeutics: List of Technology Platforms
7.3. Bispecific Antibody Technology Platforms: Comparative Analysis
7.3.1. Analysis by Technologies for Approved and Clinical Drugs
7.3.2. Analysis by Technologies for Preclinical Drugs
7.4. Most Popular Technology Platforms: Analysis by Stage of Development
7.5. Bispecific Antibody Technology Platform Developers: Analysis by Location of Headquarters
8. BIG PHARMA PLAYERS: BENCHMARKING ANALYSIS
8.1. Chapter Overview
8.2. Big Pharma Players: Benchmarking Analysis (Spider Web Representation)
8.3. Big Pharma Players: Comparative Clinical Pipeline Analysis
8.3.1. Analysis by Target Antigen
8.3.2. Analysis by Antibody Format
8.3.3. Analysis by Mechanism of Action
8.3.4. Analysis by Therapeutic Area
9. COMPANY PROFILES
9.1. Chapter Overview
9.2. Akeso Biopharma
9.2.1. Company Overview
9.2.2. Financial Performance
9.2.3. Drug Portfolio
9.2.4. Recent Developments and Future Outlook
9.3. Alphamab Oncology
9.3.1. Company Overview
9.3.2. Financial Performance
9.3.3. Drug Portfolio
9.3.4. Recent Developments and Future Outlook
9.4. Amgen
9.4.1. Company Overview
9.4.2. Financial Performance
9.4.3. Drug Portfolio
9.4.4. Recent Developments and Future Outlook
9.5. Merck
9.5.1. Company Overview
9.5.2. Financial Performance
9.5.3. Drug Portfolio
9.5.4. Recent Developments and Future Outlook
9.6. Regeneron
9.6.1. Company Overview
9.6.2. Financial Performance
9.6.3. Drug Portfolio
9.6.4. Recent Developments and Future Outlook
9.7. Roche
9.7.1. Company Overview
9.7.2. Financial Performance
9.7.3. Drug Portfolio
9.7.4. Recent Developments and Future Outlook
9.8. Xencor
9.8.1. Company Overview
9.8.2. Financial Performance
9.8.3. Drug Portfolio
9.8.4. Recent Developments and Future Outlook
10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Bispecific Antibody Therapeutics: Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Year and Type of Partnership
10.3.4. Analysis by Disease Segment
10.3.5. Analysis by Type of Payment Model Employed and Deal Amount
10.3.6. Analysis by Year of Agreement, Type of Payment Model Employed and Deal Amount
10.3.7. Analysis by Disease Segment, Type of Payment Model Employed and Deal Amount
10.3.8. Most Active Players: Analysis by Number of Partnership Instances
10.3.9. Most Popular Technologies: Analysis by Number of Partnership Instances
10.3.10. Analysis by Region
10.3.11. Intercontinental and Intracontinental Agreements
11. CONTRACT SERVICES FOR BISPECIFIC ANTIBODY THERAPEUTICS
11.1. Chapter Overview
11.2. Manufacturing of Bispecific Antibody Therapeutics
11.2.1. Key Considerations for Manufacturing and Associated Challenges
11.2.2. Contract Manufacturing Organizations (CMOs)
11.2.2.1. Bispecific Antibody Therapeutics: List of CMOs
11.2.3. Contract Research Organizations (CROs)
11.2.3.1. Bispecific Antibody Therapeutics: List of CROs
11.3. Key Considerations for Selecting a Suitable CMO / CRO Partner
12. CLINICAL TRIAL ANALYSIS
12.1. Chapter Overview
12.2. Key Assumptions and Methodology
12.3. Bispecific Antibody Therapeutics: Clinical Trial Analysis
12.3.1. Analysis by Trial Registration Year
12.3.2. Analysis of Enrolled Patient Population by Trial Registration Year
12.3.3. Analysis by Trial Phase
12.3.4. Analysis of Enrolled Patient Population by Trial Phase
12.3.5. Analysis by Trial Recruitment Status
12.3.6. Analysis by Trial Registration Year and Trial Recruitment Status
12.3.7. Analysis by Type of Study
12.3.8. Analysis by Study Design
12.3.9. Analysis by Type of Sponsor / Collaborator
12.3.10. Leading Industry Players: Analysis by Number of Registered Trials
12.3.11. Leading Non-Industry Players: Analysis by Number of Registered Trials
12.3.12. Clinical Trial Analysis: Key Focus Areas (Word Cloud Representation)
12.3.13. Analysis by Geography
12.3.14. Analysis by Trial Recruitment Status and Geography
12.3.15. Analysis of Enrolled Patient Population by Trial Recruitment Status and Geography
13. CASE STUDY: REGULATORY GUIDELINES FOR BISPECIFIC ANTIBODIES
13.1. Chapter Overview
13.2. Guidelines Issued by Regulatory Authorities
13.2.1. US Food and Drug Administration (FDA)
13.2.1.1. Pharma Companies’ Response to the FDA Draft Guidance
13.2.2. World Health Organization (WHO)
14. CASE STUDY: PROMOTIONAL / MARKETING STRATEGIES
14.1. Chapter Overview
14.2. Key Channels Used for Promotional Campaigns
14.2.1. Product Websites
14.2.2. Patient Assistance Programs
14.2.3. Participation in Conferences
14.2.4. Collaboration with Stakeholders
14.2.5. Drug Approval Across Multiple Geographies
14.3. Other Channels Used for Promotional and Marketing Strategies
14.4. Summary: Promotional and Marketing Strategy Leveraged by Bispecific Antibody Developers
14.5. Promotional Analysis: Blincyto®
14.5.1. Drug Overview
14.5.2. Product Website analysis
14.5.2.1. Messages for Healthcare Professionals
14.5.2.1.1. For MRD Positive B cell precursor ALL
14.5.2.1.2. For Relapsed or Refractory B-cell precursor ALL
14.5.2.2. Messages for Patients
14.5.3. Patient Support Services and Informative Downloads
14.5.4. Other Promotional Strategies
14.5.4.1. Presence in Conferences
14.6. Promotional Analysis: Hemlibra®
14.6.1. Drug Overview
14.6.2. Product Website Analysis
14.6.2.1. Messages for Healthcare Professionals
14.6.2.1.1. For Hemophilia A without Factor VIII Inhibitors
14.6.2.1.2. For Hemophilia A with Factor VIII Inhibitors
14.6.2.3. Messages for Patients
14.6.3. Patient Support Services and Informative Downloads
14.6.3.1. Co-pay Program
14.6.3.2. Independent Co-pay Assistance Foundation
14.6.3.3. Genentech Patient Foundation
14.6.4. Other Promotional Strategies
14.6.4.1. Presence in Conferences
15. MARKET FORECAST AND OPPORTUNITY ANALYSIS
15.1. Chapter Overview
15.2. Scope and Limitations
15.3. Forecast Methodology and Key Assumptions
15.4. Global Bispecific Antibody Therapeutics Market, 2023-2035
15.4.1. Bispecific Antibody Therapeutics Market: Analysis by Therapeutic Area, 2023 and 2035
15.4.2. Bispecific Antibody Therapeutics Market: Analysis by Mechanism of Action, 2023 and 2035
15.4.3. Bispecific Antibody Therapeutics Market: Analysis by Target Antigen, 2023 and 2035
15.4.4. Bispecific Antibody Therapeutics Market: Analysis by Antibody Format, 2023 and 2035
15.4.5. Bispecific Antibody Therapeutics Market: Analysis by Key Players, 2023 and 2035
15.4.6. Bispecific Antibody Therapeutics Market: Analysis by Geography, 2023 and 2035
15.5. Bispecific Antibody Market: Value Creation Analysis
15.6. Bispecific Antibody Therapeutics Market: Product-wise Sales Forecasts
15.6.1. AK104 (Akeso Biopharma)
15.6.1.1. Target Patient Population
15.6.1.2. Sales Forecast
15.6.1.3. Net Present Value
15.6.1.4. Value Creation Analysis
15.6.2. Blincyto™ (Amgen)
15.6.2.1. Target Patient Population
15.6.2.2. Sales Forecast
15.6.2.3. Net Present Value
15.6.2.4. Value Creation Analysis
15.6.3. Hemlibra® (Roche)
15.6.3.1. Target Patient Population
15.6.3.2. Sales Forecast
15.6.3.3. Net Present Value
15.6.3.4. Value Creation Analysis
15.6.4. Kimmtrak® (Immunocore)
15.6.4.1. Target Patient Population
15.6.4.2. Sales Forecast
15.6.4.3. Net Present Value
15.6.4.4. Value Creation Analysis
15.6.5. Lunsumio® (Roche)
15.6.5.1. Target Patient Population
15.6.5.2. Sales Forecast
15.6.5.3. Net Present Value
15.6.5.4. Value Creation Analysis
15.6.6. Nanozora® (Taisho Pharmaceutical)
15.6.6.1. Target Patient Population
15.6.6.2. Sales Forecast
15.6.6.3. Net Present Value
15.6.6.4. Value Creation Analysis
15.6.7. Rybrevant™ (Janssen Research & Development)
15.6.7.1. Target patient Population
15.6.7.2. Sales Forecast
15.6.7.3. Net Present Value
15.6.7.4. Value Creation Analysis
15.6.8. Tecvayli™ (Janssen Research & Development)
15.6.8.1. Target Patient Population
15.6.8.2. Sales Forecast
15.6.8.3. Net Present Value
15.6.8.4. Value Creation Analysis
15.6.9. Vabysmo™ (Roche)
15.6.9.1. Target Patient Population
15.6.9.2. Sales Forecast
15.6.9.3. Net Present Value
15.6.9.4. Value Creation Analysis
15.6.10. AK112 (Akeso Biopharma)
15.6.10.1. Target Patient Population
15.6.10.2. Sales Forecast
15.6.10.3. Net Present Value
15.6.10.4. Value Creation Analysis
15.6.11. ALXN1720 (Alexion)
15.6.11.1. Target Patient Population
15.6.11.2. Sales Forecast
15.6.11.3. Net Present Value
15.6.11.4. Value Creation Analysis
15.6.12. GEN3013 (Genmab)
15.6.12.1. Target Patient Population
15.6.12.2. Sales Forecast
15.6.12.3. Net Present Value
15.6.12.4. Value Creation Analysis
15.6.13. Glofitamab (Roche)
15.6.13.1. Target Patient Population
15.6.13.2. Sales Forecast
15.6.13.3. Net Present Value
15.6.13.4. Value Creation Analysis
15.6.14. LP000 (Linton Pharm)
15.6.14.1. Target Patient Population
15.6.14.2. Sales Forecast
15.6.14.3. Net Present Value
15.6.14.4. Value Creation Analysis
15.6.15. M7824 (Merck)
15.6.15.1. Target Patient Population
15.6.15.2. Sales Forecast
15.6.15.3. Net Present Value
15.6.15.4. Value Creation Analysis
15.6.16. OMP 305B83 (Mereo BioPharma)
15.6.16.1. Target Patient Population
15.6.16.2. Sales Forecast
15.6.16.3. Net Present Value
15.6.16.4. Value Creation Analysis
15.6.17. PF-06863135 (Pfizer)
15.6.17.1. Target Patient Population
15.6.17.2. Sales Forecast
15.6.17.3. Net Present Value
15.6.17.4. Value Creation Analysis
15.6.18. ZW25 (Zymeworks)
15.6.18.1. Target Patient Population
15.6.18.2. Sales Forecast
15.6.18.3. Net Present Value
15.6.18.4. Value Creation Analysis
15.7. Concluding Remarks
16. SWOT ANALYSIS
16.1. Chapter Overview
16.2. Strengths
16.2.1. Enhanced Specificity
16.2.2. Diverse Application Areas
16.2.3. Lower Drug Resistance
16.2.4. Success of Approved Products
16.3. Weaknesses
16.3.1. Uncertainties with Safety of Therapeutic Candidates
16.3.2. Complex Purification and Downstream Processing
16.3.3. Dimerization in Antibodies with Fc-region
16.4. Opportunities
16.4.1. Life Cycle Management of Novel Therapies
16.4.2. Growing Number of High Value Partnerships
16.4.3. Expertise Available with Contract Manufacturing Organizations
16.4.4. Emergence of Advanced Technologies
16.5. Threats
16.5.1. Rise in Attrition Rate of Clinical Stage Candidates
16.6. Concluding Remarks
18. EXECUTIVE INSIGHTS
18.1. Chapter Overview
18.2. CytomX Therapeutics
18.2.1. Company Snapshot
18.2.2. Interview Transcript
18.3. F-star
18.3.1. Company Snapshot
18.3.2. Interview Transcript
18.4. Immunai
18.4.1. Company Snapshot
18.4.2. Interview Transcript
18.5. Innovent Biologics
18.5.1. Company Snapshot
18.5.2. Interview Transcript
18.6. SYNIMMUNE
18.6.1. Company Snapshot
18.6.2. Interview Transcript
18.7. University of Freiburg
18.7.1. Company Snapshot
18.7.2. Interview Transcript
LIST OF FIGURES
Figure 3.1. Historical Evolution of Antibody Therapeutics
Figure 3.2. Basic Structure of an Antibody
Figure 3.3. Revenues of Top 15 Drugs, 2022 (USD Billion)
Figure 3.4. Symmetric and Asymmetric Bispecific Antibodies
Figure 4.1. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Phase of Development
Figure 4.2. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Target Antigen
Figure 4.3. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Type of Therapy
Figure 4.4. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Route of Administration
Figure 4.5. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Method of Administration
Figure 4.6. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Target Indication
Figure 4.7. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Therapeutic Area
Figure 4.8. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Disease Segment
Figure 4.9. Approved and Clinical Bispecific Antibody Therapeutics Developers: Distribution by Year of Establishment
Figure 4.10. Approved and Clinical Bispecific Antibody Therapeutics Developers: Distribution by Company Size
Figure 4.11. Approved and Clinical Bispecific Antibody Therapeutics Developers: Distribution by Location of Headquarters
Figure 5.1. Preclinical Bispecific Antibody Therapeutics: Distribution by Stage of Development
Figure 5.2. Preclinical Bispecific Antibody Therapeutics: Distribution by Target Antigen
Figure 5.3. Preclinical Bispecific Antibody Therapeutics: Distribution by Disease Segment
Figure 5.4. Preclinical Bispecific Antibody Therapeutics Developers: Distribution by Year of Establishment
Figure 5.5. Preclinical Bispecific Antibody Therapeutics Developers: Distribution by Company Size
Figure 5.6. Preclinical Bispecific Antibody Therapeutics Developers: Distribution by Location of Headquarters
Figure 6.1. Approved and Clinical Stage Bispecific Antibody Therapeutics Landscape: Distribution by Phase of Development and Route of Administration
Figure 6.2. Approved and Clinical Stage Bispecific Antibody Therapeutics Landscape: Distribution by Phase of Development and Disease Segment
Figure 6.3. Approved and Clinical Stage Bispecific Antibody Therapeutics Landscape: Distribution by Phase of Development and Location of Developer Headquarters
Figure 6.4. Preclinical Stage Bispecific Antibody Therapeutics Landscape: Distribution by Stage of Development and Therapeutic Area
Figure 6.5. Preclinical Stage Bispecific Antibody Therapeutics Landscape: Distribution by Stage of Development and Location of Developer Headquarters
Figure 6.6. Bispecific Antibody Therapeutics Developers Landscape: Distribution by Stage of Development
Figure 6.7. Bispecific Antibody Therapeutics Developers Landscape: Distribution by Stage of Development and Region of Developer Headquarters
Figure 7.1. Technology Platforms for Approved and Clinical Bispecific Antibodies: Comparative Analysis
Figure 7.2. Technology Platforms for Preclinical Bispecific Antibodies: Comparative Analysis
Figure 7.3. Most Popular Technology Platforms: Distribution by Stage of Development
Figure 7.4. Bispecific Antibody Technology Platform Developers: Distribution by Location of Headquarters
Figure 8.1. Big Pharma Players: Benchmarking Analysis (Spider Web Representation)
Figure 8.2. Big Pharma Players: Distribution by Target Antigen
Figure 8.3. Big Pharma Players: Distribution by Antibody Format
Figure 8.4. Big Pharma Players: Distribution by Mechanism of Action
Figure 8.5. Big Pharma Players: Distribution by Therapeutic Area
Figure 9.1. Akeso Biopharma: Annual Revenues, 2019 - 2022 (RMB Million)
Figure 9.2. Alphamab Oncology: Annual Revenues, 2019 - H1 2022 (RMB Million)
Figure 9.3. Amgen: Annual Revenues, 2019 - 2022 (USD Billion)
Figure 9.4. Merck: Annual Revenues, 2019 - H1 2022 (EUR Billion)
Figure 9.5. Regeneron: Annual Revenues, 2019 - 2022 (USD Billion)
Figure 9.6. Roche: Annual Revenues, 2019 - 2022 (CHF Million)
Figure 9.7. Xencor: Annual Revenues, 2019 - 2022 (USD Million)
Figure 10.1. Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2023
Figure 10.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3. Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 10.4. Partnerships and Collaborations: Distribution by Disease Segment
Figure 10.5. Partnerships and Collaborations: Distribution by Type of Payment Model Employed and Deal Amount (USD Billion)
Figure 10.6. Partnerships and Collaborations: Year-wise Distribution by Type of Payment Model Employed and Deal Amount (USD Billion, 2016-2023)
Figure 10.7. Partnerships and Collaborations: Distribution by Disease Segment, Type of Payment Model Employed and Deal Amount (USD Billion)
Figure 10.8. Most Active Players: Distribution by Number of Partnership Instances
Figure 10.9. Most Popular Technologies: Distribution by Number of Partnership Instances
Figure 10.10. Partnerships and Collaborations: Distribution by Region
Figure 10.11. Partnerships and Collaborations: International and Intracontinental Agreements
Figure 12.1. Clinical Trial Analysis: Cumulative Year-wise Trend of Trials by Trial Registration Year, Pre-2010-2023
Figure 12.2. Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, Pre-2010-2023
Figure 12.3. Clinical Trial Analysis: Distribution by Trial Phase
Figure 12.4. Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 12.5. Clinical Trial Analysis: Distribution by Trial Recruitment Status
Figure 12.6. Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year and Trial Recruitment Status
Figure 12.7. Clinical Trial Analysis: Distribution by Type of Study
Figure 12.8. Clinical Trial Analysis: Distribution by Study Design
Figure 12.9. Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 12.10. Leading Industry Players: Distribution by Number of Registered Trials
Figure 12.11. Leading Non-Industry Players: Distribution by Number of Registered Trials
Figure 12.12. Clinical Trial Analysis: Key Focus Areas (Word Cloud Representation)
Figure 12.13. Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
Figure 12.14. Clinical Trial Analysis: Geographical Distribution by Trial Recruitment Status
Figure 12.15. Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population by Trial Recruitment Status
Figure 13.1. FDA Considerations for Development of Bispecific Antibodies
Figure 14.1. Key Channels Used for Promotional and Marketing Campaigns
Figure 14.2. Blincyto®: Product Website Snapshots (Messages for Healthcare Professionals, BLAST Study Results)
Figure 14.3. Blincyto®: Product Website Snapshots (Messages for Healthcare Professionals, TOWER Study Results)
Figure 14.4. Blincyto®: Product Website Snapshots (Messages for Healthcare Professionals, Ph (+) Relapsed / Refractory B-cell Precursor ALL)
Figure 14.5. Blincyto®: Product Website Snapshots (Messages for Healthcare Professionals, Relapsed / Refractory B-cell Precursor ALL (Pediatrics))
Figure 14.6. Blincyto®: Product Website Snapshots (Messages for Patients)
Figure 14.7. Blincyto®: Amgen Assist 360 Nurse Ambassador
Figure 14.8. Blincyto®: Presence in Conferences
Figure 14.9. Hemlibra®: Product Website Snapshots (Messages for Healthcare Professionals, Hemophilia A without Factor VIII Inhibitors)
Figure 14.10. Hemlibra®: Product Website Snapshots (Messages for Healthcare Professionals, Hemophilia A with Factor VIII Inhibitors)
Figure 14.11. Hemlibra®: Product Website Snapshots (Messages for Patients)
Figure 14.12. Hemlibra®: Presence in Conferences
Figure 15.1. Global Bispecific Antibody Therapeutics Market, 2023-2035 (USD Million)
Figure 15.2. Bispecific Antibody Therapeutics Market: Distribution by Therapeutic Area, 2023 and 2035 (USD Million)
Figure 15.3. Bispecific Antibody Therapeutics Market: Distribution by Mechanism of Action, 2023 and 2035 (USD Million)
Figure 15.4. Bispecific Antibody Therapeutics Market: Distribution by Target Antigen, 2023 and 2035 (USD Million)
Figure 15.5. Bispecific Antibody Therapeutics Market: Distribution by Antibody Format, 2023 and 2035 (USD Million)
Figure 15.6. Bispecific Antibody Therapeutics Market: Distribution by Key Players, 2023 and 2035 (USD Million)
Figure 15.7. Bispecific Antibody Therapeutics Market: Distribution by Geography, 2023 and 2035 (USD Million)
Figure 15.8. AK104 (Akeso Biopharma) Sales Forecast, Till 2035 (USD Million)
Figure 15.9. Blincyto® (Amgen) Sales Forecast, Till 2035 (USD Million)
Figure 15.10. Hemlibra® (Roche) Sales Forecast, Till 2035 (USD Million)
Figure 15.11 Kimmtrak® (Immunocore) Sales Forecast, Till 2035 (USD Million)
Figure 15.12. Lunsumio® (Roche) Sales Forecast, Till 2035 (USD Million)
Figure 15.13. Nanozora® (Taisho Pharmaceutical) Sales Forecast, Till 2035 (USD Million)
Figure 15.14. Rybrevant™ (Janssen Research & Development) Sales Forecast, Till 2035 (USD Million)
Figure 15.15. Tecvayli™ (Janssen Research & Development) Sales Forecast, Till 2035 (USD Million)
Figure 15.16. Vabysmo™ (Roche) Sales Forecast, Till 2035 (USD Million)
Figure 15.17. AK112 (Akeso Biopharma) Sales Forecast, Till 2035 (USD Million)
Figure 15.18. ALXN1720 (Alexion) Sales Forecast, Till 2035 (USD Million)
Figure 15.19. GEN3013 (Genmab) Sales Forecast, Till 2035 (USD Million)
Figure 15.20. Glofitamab (Roche) Sales Forecast, Till 2035 (USD Million)
Figure 15.21. LP000 (Linton Pharm) Sales Forecast, Till 2035 (USD Million)
Figure 15.22. M7824 (Merck) Sales Forecast, Till 2035 (USD Million)
Figure 15.23. OMP 305B83 (Mereo BioPharma) Sales Forecast, Till 2035 (USD Million)
Figure 15.24. PF-06863135 (Pfizer) Sales Forecast, Till 2035 (USD Million)
Figure 15.25. ZW25 (Zymeworks) Sales Forecast, Till 2035 (USD Million)
Figure 16.1. Bispecific Antibody Therapeutics: SWOT Analysis
Figure 16.2. Comparison of SWOT Factors: Harvey Ball Analysis
LIST OF TABLES
Table 3.1. Isotypes of Mammalian Antibodies
Table 3.2. Mechanisms of Action of Antibody Therapeutics
Table 3.3. Revenue of Top Antibody Therapeutics, 2022 (USD Billion)
Table 4.1. Bispecific Antibody Therapeutics: Information on Approved and Clinical Drug Candidates, Developer(s), Phase of Development and Target Antigen
Table 4.2. Bispecific Antibody Therapeutics: Information on Approved and Clinical Drug Candidates, Type of Therapy, Route of Administration and Method of Administration
Table 4.3. Bispecific Antibody Therapeutics: Information on Approved and Clinical Drug Candidates, Target Indication(s), Therapeutic Area(s) and Disease Segment(s)
Table 4.4. Bispecific Antibody Therapeutics Developers: Information on Approved and Clinical Drug Candidates Developers, Year of Establishment, Company Size, Location of Headquarters
Table 5.1. Bispecific Antibody Therapeutics: Information on Preclinical Drug Candidates, Developer(s), Stage of Development and Target Antigen
Table 5.2. Bispecific Antibody Therapeutics: Information on Preclinical Drug Candidates, Developer(s), Therapeutic Area(s) and Disease Segment(s)
Table 5.3. Bispecific Antibody Therapeutics Developers: Information on Preclinical Drug Candidates Developers, Year of Establishment, Company Size, Location of Headquarters
Table 7.1. Bispecific Antibody Therapeutics: List of Technology Platforms
Table 9.1. Bispecific Antibody Therapeutics Developers: List of Companies Profiled
Table 9.2. Akeso Biopharma: Company Overview
Table 9.3. Akeso Biopharma: Bispecific Antibody Therapeutics Portfolio
Table 9.4. Akeso Biopharma: Recent Developments and Future Outlook
Table 9.5. Alphamab Oncology: Company Overview
Table 9.6. Alphamab Oncology: Bispecific Antibody Therapeutics Portfolio
Table 9.7. Alphamab Oncology: Recent Developments and Future Outlook
Table 9.8. Amgen: Company Overview
Table 9.9. Amgen: Bispecific Antibody Therapeutics Portfolio
Table 9.10. Amgen: Recent Developments and Future Outlook
Table 9.11. Merck: Company Overview
Table 9.12. Merck: Bispecific Antibody Therapeutics Portfolio
Table 9.13. Merck: Recent Developments and Future Outlook
Table 9.14. Regeneron: Company Overview
Table 9.15. Regeneron: Bispecific Antibody Therapeutics Portfolio
Table 9.16. Regeneron: Recent Developments and Future Outlook
Table 9.17. Roche: Company Overview
Table 9.18. Roche: Bispecific Antibody Therapeutics Portfolio
Table 9.19. Roche: Recent Developments and Future Outlook
Table 9.20. Xencor: Company Overview
Table 9.21. Xencor: Bispecific Antibody Therapeutics Portfolio
Table 9.22. Xencor: Recent Developments and Future Outlook
Table 10.1. Partnerships and Collaborations: Information on Year of Agreement, Partner and Type of Agreement, 2016-2023
Table 10.2. Partnerships and Collaborations: Information on Type of Agreement (Region-wise and Geography-wise), 2016-2023
Table 11.1. List of Bispecific Antibody CMOs: Company Specifications
Table 11.2. List of Bispecific Antibody CMOs: Information on Scale of Operation
Table 11.3. List of Bispecific Antibody CROs: Company Specifications
Table 11.4. List of Bispecific Antibody CROs: Information on Type of Service
Table 11.5. Comparison of Key Factors for the Selection of Contract Service Provider: Harvey Ball Analysis
Table 14.1. List of Bispecific Antibodies Approved Across Various Geographies
Table 15.1. Bispecific Antibody Therapeutics: Expected Launch Years of Advanced Stage Drug Candidates
Table 15.2. AK104: Target Patient Population
Table 15.3. AK104: Net Present Value (USD Million)
Table 15.4. AK104: Value Creation Analysis (USD Million)
Table 15.5. Blincyto®: Target Patient Population
Table 15.6. Blincyto®: Net Present Value (USD Million)
Table 15.7. Blincyto®: Value Creation Analysis (USD Million)
Table 15.8. Hemlibra®: Target Patient Population
Table 15.9. Hemlibra®: Net Present Value (USD Million)
Table 15.10. Hemlibra®: Value Creation Analysis (USD Million)
Table 15.11. Kimmtrak®: Target Patient Population
Table 15.12. Kimmtrak®: Net Present Value (USD Million)
Table 15.13. Kimmtrak®: Value Creation Analysis (USD Million)
Table 15.14. Lunsumio®: Target Patient Population
Table 15.15. Lunsumio®: Net Present Value (USD Million)
Table 15.16. Lunsumio®: Value Creation Analysis (USD Million)
Table 15.17. Nanozora®: Target Patient Population
Table 15.18. Nanozora®: Net Present Value (USD Million)
Table 15.19. Nanozora®: Value Creation Analysis (USD Million)
Table 15.20. Rybrevant™: Target Patient Population
Table 15.21. Rybrevant™: Net Present Value (USD Million)
Table 15.22. Rybrevant™: Value Creation Analysis (USD Million)
Table 15.23. Tecvayli™: Target Patient Population
Table 15.24. Tecvayli™: Net Present Value (USD Million)
Table 15.25. Tecvayli™: Value Creation Analysis (USD Million)
Table 15.26. Vabysmo™: Target Patient Population
Table 15.27. Vabysmo™: Net Present Value (USD Million)
Table 15.28. Vabysmo™: Value Creation Analysis (USD Million)
Table 15.29. AK112: Target Patient Population
Table 15.30. AK112: Net Present Value (USD Million)
Table 15.31. AK112: Value Creation Analysis (USD Million)
Table 15.32. ALXN1720: Target Patient Population
Table 15.33. ALXN1720: Net Present Value (USD Million)
Table 15.34. ALXN1720: Value Creation Analysis (USD Million)
Table 15.35. GEN3013: Target Patient Population
Table 15.36. GEN3013: Net Present Value (USD Million)
Table 15.37. GEN3013: Value Creation Analysis (USD Million)
Table 15.38. Glofitamab: Target Patient Population
Table 15.39. Glofitamab: Net Present Value (USD Million)
Table 15.40. Glofitamab: Value Creation Analysis (USD Million)
Table 15.41. LP000: Target Patient Population
Table 15.42. LP000: Net Present Value (USD Million)
Table 15.43. LP000: Value Creation Analysis (USD Million)
Table 15.44. M7824: Target Patient Population
Table 15.45. M7824: Net Present Value (USD Million)
Table 15.46. M7824: Value Creation Analysis (USD Million)
Table 15.47. OMP 305B83: Target Patient Population
Table 15.48. OMP 305B83: Net Present Value (USD Million)
Table 15.49. OMP 305B83: Value Creation Analysis (USD Million)
Table 15.50. PF-06863135: Target Patient Population
Table 15.51. PF-06863135: Net Present Value (USD Million)
Table 15.52. PF-06863135: Value Creation Analysis (USD Million)
Table 15.53. ZW25: Target Patient Population
Table 15.54. ZW25: Net Present Value (USD Million)
Table 15.55. ZW25: Value Creation Analysis (USD Million)
Table 18.1. CytomX Therapeutics: Company Snapshot
Table 18.2. F-star: Company Snapshot
Table 18.3. Immunai: Company Snapshot
Table 18.4. Innovent Biologics: Company Snapshot
Table 18.5. SYNIMMUNE: Company Snapshot
Table 18.6. University of Freiburg: Organization Snapshot
Table 19.1. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Phase of Development
Table 19.2. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Target Antigen
Table 19.3. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Type of Therapy
Table 19.4. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Route of Administration
Table 19.5. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Method of Administration
Table 19.6. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Target Indication
Table 19.7. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Therapeutic Area
Table 19.8. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Disease Segment
Table 19.9. Approved and Clinical Bispecific Antibody Therapeutics Developers: Distribution by Year of Establishment
Table 19.10. Approved and Clinical Bispecific Antibody Therapeutics Developers: Distribution by Company Size
Table 19.11. Approved and Clinical Bispecific Antibody Therapeutics Developers: Distribution by Location of Headquarters
Table 19.12. Preclinical Bispecific Antibody Therapeutics: Distribution by Stage of Development
Table 19.13. Preclinical Bispecific Antibody Therapeutics: Distribution by Target Antigen
Table 19.14. Preclinical Bispecific Antibody Therapeutics: Distribution by Disease Segment
Table 19.15. Preclinical Bispecific Antibody Therapeutics Developers: Distribution by Year of Establishment
Table 19.16. Preclinical Bispecific Antibody Therapeutics Developers: Distribution by Company Size
Table 19.17. Preclinical Bispecific Antibody Therapeutics Developers: Distribution by Location of Headquarters
Table 19.18. Most Popular Technology Platforms: Distribution by Stage of Development
Table 19.19. Bispecific Antibody Technology Platform Developers: Distribution by Location of Headquarters
Table 19.20. Akeso Biopharma: Annual Revenues, 2019 - 2022 (RMB Million)
Table 19.21. Alphamab Oncology: Annual Revenues, 2019 - H1 2022 (RMB Million)
Table 19.22. Amgen: Annual Revenues, 2019 - 2022 (USD Billion)
Table 19.23. Merck: Annual Revenues, 2019 - H1 2022 (EUR Billion)
Table 19.24. Regeneron: Annual Revenues, 2019 - 2022 (USD Billion)
Table 19.25. Roche: Annual Revenues, 2019 - 2022 (CHF Million)
Table 19.26. Xencor: Annual Revenues, 2019 - 2022 (USD Million)
Table 19.27. Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2023
Table 19.28. Partnerships and Collaborations: Distribution by Type of Partnership
Table 19.29. Partnerships and Collaborations: Distribution by Disease Segment
Table 19.30. Partnerships and Collaborations: Distribution by Type of Payment Model Employed and Deal Amount (USD Billion)
Table 19.31. Partnerships and Collaborations: Year-wise Distribution by Type of Payment Model Employed and Deal Amount (USD Billion, 2016-2023)
Table 19.32. Partnerships and Collaborations: Distribution by Disease Segment, Type of Payment Model Employed and Deal Amount (USD Billion)
Table 19.33. Most Active Players: Distribution by Number of Partnership Instances
Table 19.34. Most Popular Technologies: Distribution by Number of Partnership Instances
Table 19.35. Partnerships and Collaborations: Distribution by Region
Table 19.36. Partnerships and Collaborations: International and Intracontinental Agreements
Table 19.37. Clinical Trial Analysis: Cumulative Year-wise Trend of Trials by Trial Registration Year, Pre-2010-2023
Table 19.38. Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, Pre-2010-2023
Table 19.39. Clinical Trial Analysis: Distribution by Trial Phase
Table 19.40. Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 19.41. Clinical Trial Analysis: Distribution by Trial Recruitment Status
Table 19.42. Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year and Trial Recruitment Status
Table 19.43. Clinical Trial Analysis: Distribution by Type of Study
Table 19.44. Clinical Trial Analysis: Distribution by Study Design
Table 19.45. Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 19.46. Clinical Trial Analysis: Geographical Distribution by Trial Recruitment Status
Table 19.47. Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population by Trial Recruitment Status
Table 19.48. Global Bispecific Antibody Therapeutics Market, Conservative, Base, and Optimistic Scenarios, 2023-2035 (USD Million)
Table 19.49. Bispecific Antibody Therapeutics Market: Distribution by Therapeutic Area, Conservative, Base, and Optimistic Scenarios, 2023 and 2035 (USD Million)
Table 19.50. Bispecific Antibody Therapeutics Market: Distribution by Mechanism of Action, Conservative, Base, and Optimistic Scenarios, 2023 and 2035 (USD Million)
Table 19.51. Bispecific Antibody Therapeutics Market: Distribution by Target Antigen, Conservative, Base, and Optimistic Scenarios, 2023 and 2035 (USD Million)
Table 19.52. Bispecific Antibody Therapeutics Market: Distribution by Antibody Format, Conservative, Base, and Optimistic Scenarios, 2023 and 2035 (USD Million)
Table 19.53. Bispecific Antibody Therapeutics Market: Distribution by Key Players, Conservative, Base, and Optimistic Scenarios, 2023 and 2035 (USD Million)
Table 19.54. Bispecific Antibody Therapeutics Market: Distribution by Geography, Conservative, Base, and Optimistic Scenarios, 2023 and 2035 (USD Million)
Table 19.55. AK104 (Akeso Biopharma) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.56. Blincyto® (Amgen) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.57. Hemlibra® (Roche) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.58. Kimmtrak® (Immunocore) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.59. Lunsumio® (Roche) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.60. Nanozora® (Taisho Pharmaceutical) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.61. Rybrevant™ (Janssen Research & Development) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.62. Tecvayli™ (Janssen Research & Development) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.63. Vabysmo™ (Roche) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.64. AK112 (Akeso Biopharma) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.65. ALXN1720 (Alexion) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.66. GEN3013 (Genmab) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.67. Glofitamab (Roche) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.68. LP000 (Linton Pharm) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.69. M7824 (Merck) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.70. OMP 305B83 (Mereo BioPharma) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.71. PF-06863135 (Pfizer) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.72. ZW25 (Zymeworks) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
